Austin, Texas and Auckland, New Zealand (PRWEB) September 10, 2013
Emergent Technologies, Inc. a leading innovation solutions company and KODE Biotech, Ltd, developer of the revolutionary KODE™ biosurface modification technology, have entered into a commercialization agreement in which Emergent will be KODE Biotech’s agent for technology commercialization. The agreement provides for revenue sharing between Emergent and KODE Biotech and has the potential to generate $5 – 10M in annual licensing revenues.
Biological processes are mediated by cell-cell and cell-surface interactions. KODE™ biosurface modification technology provides “biological paints” that can be used to apply virtually any bioactive compound to virtually any surface in just minutes without the need for any specialized equipment.
“Our technology represents a platform of constructs that can be used to modify cells, viruses, gels, solutions and solids such as glass and metal,” said Steve Henry, KODE Biotech’s CEO/CSO and Professor of Biotech Innovation at the Auckland University of Technology (AUT) Biotech Innovation Centre. “We have a proven track record in the transfusion medicine industry, where our products are being used to make quality controls and specialized diagnostic screening assays in a variety of novel diagnostic and therapeutic products."
“KODE Biotech’s technological capabilities and broad platform are a perfect fit for our innovation-based, partner-driven model,” said Thomas Harlan, Emergent CEO. “Our expertise is in locating, engaging and executing licensing deals between established companies looking for innovative solutions to protect and grow their core businesses and smaller companies like KODE Biotech that have developed such technology but lack the infrastructure and resources to see it reach its full commercialization potential.”
Under the terms of the agreement, Emergent will pursue existing leads, identify new areas of application, and process new business development opportunities from its headquarters in Austin. KODE Biotech will continue with its current commercialization, but shift to focus more on R&D from its on-campus base at AUT University providing Proof-of-Concept studies for the new business development opportunities. The companies are evaluating a KODE™-branded market-facing entity to be established in the US, from which Emergent will conduct KODE™ commercialization related business.
About Emergent Technologies, Inc.
Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) utilizes its innovation-based, partner-driven model to identify, manage, develop and bring to market game-changing scientific discoveries. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. Emergent applies its experience and expertise to provide investors, entrepreneurs, start-up companies and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. Visit http://www.emergenttechnologies.com for more information.
About KODE Biotech, Ltd
Based on the AUT University campus in Auckland, New Zealand, KODE Biotech, Ltd is a private company established in 1996 to commercialize and license use of KODE™ biosurface modification technology. Working together with AUT University (http://www.aut.ac.nz/), KODE Biotech has developed the platform for rapid modification of virtually any surface with any functional molecule without the need for special equipment or processes. KODE™ biosurface modification technology offers significant opportunities for industrial and life science innovation and product improvement. For more information, visit the KODE Biotech website at http://www.kodebiotech.com.